- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/485 - Epidermal growth factor [EGF], i.e. urogastrone
Patent holdings for IPC class C07K 14/485
Total number of patents in this class: 327
10-year publication summary
26
|
21
|
23
|
32
|
27
|
28
|
20
|
19
|
16
|
9
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Modernatx, Inc. | 1296 |
28 |
Silver Creek Pharmaceuticals, Inc. | 29 |
9 |
In3bio Ltd. | 23 |
8 |
Gladiator Biosciences, Inc. | 14 |
7 |
The Regents of the University of California | 20137 |
6 |
Affibody AB | 115 |
6 |
NEXGEN Biotechnologies, Inc. | 47 |
6 |
Zymeworks Inc. | 262 |
6 |
Nexel Co., Ltd. | 26 |
6 |
IGF Oncology, LLC | 16 |
5 |
Immunwork Inc. | 26 |
5 |
Sun Kyo Lee | 18 |
5 |
Mind-NRG SARL | 4 |
4 |
Regents of the University of Minnesota | 2711 |
4 |
Novo Nordisk A/S | 2279 |
4 |
Shanghai Synvida Biotechnology Co. Ltd. | 16 |
4 |
The Board of Trustees of the Leland Stanford Junior University | 6487 |
3 |
Board of Regents, The University of Texas System | 5884 |
3 |
President and Fellows of Harvard College | 6005 |
3 |
Ansun Biopharma, Inc. | 49 |
3 |
Other owners | 202 |